
News|Articles|June 21, 2004
Now there's safe, effective relief for innocents abroad
Clinicians can now offer their patients the first nonsystemic, gastrointestinal selective antibiotic to receive FDA approval. The agency recently approved rifaximin (Xifaxan, Salix Pharmaceuticals) tablets for the treatment of TD caused by noninvasive strains of Escherichia coli in those 12 years of age or older. Rifaximin is currently approved for use in 17 countries worldwide. It is expected to be available in U.S. pharmacies in August.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Q&A: Expert States Loudest Medical Content on Social Media Is Typically Negative
2
The Regimen: Pharmacists Bridging the Treatment Gap for Patients with OUD
3
Community Pharmacies Face Barriers Amid PBM Practices, Industry Shifts
4
Evoke Trials Show No Alzheimer Reduction Among Semaglutide Users
5





































































































































